Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Xanax · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Alprazolam Extended-Release Tablets 1 mg |
| 2 | ACTIVE_COMPARATOR | Xanax XR Tablets 1 mg |
| Name | Type | Description |
|---|---|---|
| Alprazolam Extended-Release Tablets 1 mg | DRUG | - |
| Xanax XR Tablets 1 mg | DRUG | - |
| Alprazolam Extended-Release Tablets 3 mg | DRUG | 3mg, single dose fasting |
| Xanax XR® Tablets (3 mg | DRUG | 3mg, single dose fasting |
| Xanax XR® Tablets 3 mg | DRUG | 3mg, single dose fed |
Inclusion Criteria: * 1\. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the ...
Xanax is used for the treatment of anxiety and panic disorders. It is a small molecule drug developed by Viatris Inc. (VTRS). The drug is currently in Phase 1 clinical development, with ongoing studies evaluating its safety and pharmacokinetics in healthy volunteers.
Xanax is developed by Viatris Inc., a global healthcare company traded on the NASDAQ under the ticker VTRS. The company is conducting Phase 1 clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
Xanax is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The Phase 1 trials are designed to assess the drug's safety, tolerability, and pharmacokinetic profile in healthy volunteers.
Xanax has completed three Phase 1 clinical trials, all conducted in the United States. These include NCT00647634, NCT00647894, and NCT00650299, which evaluated the fasting and fed pharmacokinetics of alprazolam extended-release tablets compared to Xanax XR tablets in healthy volunteers.
Xanax is a brand name for alprazolam. The clinical trials for Xanax are studies of alprazolam extended-release tablets, comparing them to the reference product Xanax XR. These studies are conducted in healthy volunteers to assess bioequivalence.